What Abionic does

Abionic SA is a Swiss medical diagnostics company founded in 2010 as a spin-off from EPFL (École Polytechnique Fédérale de Lausanne), headquartered at the Biopôle Lausanne campus in Epalinges, Switzerland. The company develops and commercializes the abioSCOPE®, a near-patient in vitro diagnostic platform based on proprietary nanofluidic immunoassay technology. The platform reads single-use disposable cartridges, most prominently the IVD CAPSULE PSP, which measures Pancreatic Stone Protein (Pancreatic Stone Protein) to enable early sepsis detection up to 72 hours before clinical recognition, delivering quantitative results in approximately 7 minutes from a single 50 µL drop of whole blood. The company also markets an IVD CAPSULE D-DIMER cartridge and integrates with hospital and laboratory information systems.

Abionic's commercial focus is on acute hospital settings where time-to-diagnosis drives outcomes: Emergency Departments, Intensive Care Units, Burn Units and high-acuity Wards. The technology is CE marked, IVDR certified (July 2022), ISO 13485:2016 certified, and FDA 510(k) cleared (October 2024) for the PSP assay, with pediatric approval added in January 2026. The PSP biomarker is now recognized in the 2026 Surviving Sepsis Campaign International Guidelines. The company has built a clinical evidence base of more than 50 peer-reviewed publications validating PSP performance across multiple care settings.

Abionic generates revenue through a razor/blade model combining capital sales of the abioSCOPE reader with recurring sales of single-use IVD Capsule cartridges. Pricing is not publicly disclosed; sales are conducted via a direct B2B enterprise motion targeting hospital leadership, sepsis coordinators and clinical staff. The company has commercial presence in 14+ countries across Europe, the United States, China and Brazil, and employs 11-50 people. Total disclosed funding since inception is approximately CHF 36.7 million across Series A (2012), Series B (2014) and Series C (2017) rounds. Leadership transitioned in April 2024, with Patrick Pestalozzi replacing founder Nicolas Durand as CEO.

Name

Abionic

Legal name

Abionic SA

Website

https://abionic.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Abionic SA is a Swiss diagnostics company that develops the abioSCOPE® nanofluidic point-of-care platform and the IVD CAPSULE PSP assay for early sepsis detection, selling directly to hospital Emergency Departments, ICUs, Burn Units and Wards across Europe and the United States.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostic Medical Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

Keywords

• Point-of-care diagnostics
• Sepsis detection
• Nanofluidic immunoassay
• In vitro diagnostics
• Rapid blood testing

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Diagnostic Devices and Consumables: Abionic generates revenue through the sale of its abioSCOPE diagnostic platform (capital equipment) and associated IVD Capsule consumables (single-use test cartridges). The recurring consumables model provides recurring revenue as hospitals perform tests on patients suspected of sepsis.
2. IVD Capsule PSP Test: Sale of IVD Capsule PSP test cartridges for sepsis detection, available for use in critical care and emergency settings. Revenue derived from both direct hospital sales and potentially through distribution partnerships as the company expands into the US market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Abionic develops and commercializes the abioSCOPE® near-patient rapid in vitro diagnostic platform based on proprietary nanofluidic immunoassay technology. The platform reads disposable IVD CAPSULE cartridges from a single drop of whole blood, with its flagship assay IVD CAPSULE PSP measuring Pancreatic Stone Protein to enable early sepsis detection in approximately 7 minutes across hospital Emergency Departments, ICUs, Burn Units, and Wards.

Product overview

Abionic offers a unified diagnostic ecosystem centered on the abioSCOPE® platform, a near-patient rapid diagnostic system that uses nanofluidic immunoassay technology to deliver lab-quality results within minutes from a single drop of blood. The core assay is the IVD CAPSULE PSP (Pancreatic Stone Protein), which runs exclusively on the abioSCOPE® and enables early sepsis detection up to 72 hours before clinical recognition. Additional test cartridges include the IVD CAPSULE D-DIMER. The platform's disposable cartridges contain test-specific biosensors and support single-cartridge multiplex testing. The system integrates with Hospital Information Systems (HIS) and Laboratory Information Systems (LIS) for seamless clinical workflow integration.

Differentiator

Problem solved

Functional benefit

Brands

• abioSCOPE: Near-patient rapid in vitro diagnostic platform using nanofluidic immunoassay technology that delivers lab-quality results within minutes from a single drop of whole blood. The device reads disposable cartridges containing test-specific biosensors.
• IVD CAPSULE PSP

Products and services

• abioSCOPE® The abioSCOPE® is a near-patient rapid in vitro diagnostic platform using proprietary nanofluidic immunoassay technology to deliver lab-quality quantitative, semi-quantitative, or qualitative results within minutes from a single 50 µL drop of whole blood. It reads disposable single-use IVD CAPSULE cartridges containing test-specific biosensors and integrates with Hospital Information Systems and Laboratory Information Systems for clinical workflow integration. Intended for hospital Emergency Departments, Intensive Care Units, Burn Units, and Wards performing rapid sepsis screening.
• IVD CAPSULE PSP (Pancreatic Stone Protein) IVD CAPSULE PSP is a single-use disposable diagnostic cartridge that measures Pancreatic Stone Protein (Pancreatic Stone Protein) levels from a drop of blood, running exclusively on the abioSCOPE® platform. Results are delivered in approximately 7 minutes, enabling detection of sepsis up to 72 hours before clinical recognition and discriminating septic patients from those with non-infectious systemic inflammatory response syndrome. FDA 510(k) cleared, IVDR certified for both adults and children, and recognized in the 2026 Surviving Sepsis Campaign International Guidelines as a sepsis risk biomarker.
• IVD CAPSULE D-DIMER IVD CAPSULE D-DIMER is a rapid diagnostic test cartridge for D-Dimer detection, CE marked in 2022 and designed to run on the abioSCOPE® platform for hospital point-of-care use.

Quantifiable outcome

• PSP levels rise up to 72 hours before clinical sepsis recognition
• +4 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered foundational and core.

• EPFL (École Polytechnique Fédérale de Lausanne)foundationalStrategic or Co-development PartnerAbionic was founded in 2010 as a spin-off from EPFL, Switzerland's premier technical university. The company leverages technology developed at the university for its nanofluidic diagnostic platform. This foundational academic partnership provided the core technology IP for the abioSCOPE platform.
• Biopôle LausannecoreStrategic or Co-development PartnerAbionic is headquartered at Biopôle Lausanne, a premier life sciences campus in Switzerland. The company moved to new facilities at Biopôle in 2016. This location provides access to the Swiss medtech ecosystem, talent pool, and collaborative research opportunities.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• T2 Biosystems: T2 Biosystems develops rapid molecular diagnostics for sepsis and other bloodstream infections, directly competing with Abionic in the rapid sepsis diagnostics category at hospital point-of-care.
• Cytovale: Cytovale's IntelliSep is a rapid cellular biomarker test for sepsis that delivers results in under 10 minutes from a blood sample, directly competing with Abionic's abioSCOPE PSP test in ED and hospital settings.

Emerging players

• Inflammatix: Inflammatix is developing host-response based rapid diagnostics for acute infections and sepsis, addressing the same clinical decision point as Abionic's PSP test with a different biomarker approach.
• EKF Diagnostics: EKF Diagnostics develops point-of-care analyzers and rapid biomarker tests for hospital use, including inflammatory markers; a smaller niche player comparable to Abionic in scale and POC focus.

Broad incumbents

• bioMérieux: bioMérieux is a global IVD leader offering PCT (procalcitonin) and other sepsis biomarkers through its VIDAS and BioFire platforms, representing the entrenched incumbent benchmark that PSP competes against in hospital sepsis workups.
• B·R·A·H·M·S / Thermo Fisher Scientific: B·R·A·H·M·S (Thermo Fisher) owns the dominant PCT biomarker for sepsis diagnosis (BRAHMS PCT), which is the most established non-CRP sepsis marker and a direct substitute for Abionic's PSP positioning.
• Roche Diagnostics: Roche Diagnostics offers a broad hospital IVD menu including CRP, PCT, and lactate sepsis markers via cobas platforms, and is the dominant incumbent in hospital central lab diagnostics globally.
• Abbott Point of Care: Abbott's i-STAT and rapid POC platforms are installed across thousands of US EDs and ICUs, representing the entrenched POC infrastructure that Abionic's abioSCOPE must displace or co-exist with for sepsis testing.
• QuidelOrtho: QuidelOrtho offers a broad IVD portfolio including hospital sepsis biomarkers (CRP, PCT) on its Vitros and Sofia platforms, competing for the same hospital budget allocations as Abionic.

Others

• Axis-Shield (Abbott): Axis-Shield (now part of Abbott) developed the original CRP and other biomarker POC tests; relevant as a historical comparator and technology lineage reference for Abionic's POC sepsis positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInch.linkedin.com/company/abionic
• Xx.com/abionic_en
• Facebookfacebook.com/abionic.ch

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abionic